Deallus Consulting is a global life-sciences management consultancy with deep scientific and business expertise represented in the backgrounds of each of the individuals on our team.We provide innovative, best in class strategy consulting and competitive insights for industry leaders who define, lead and inform brand, franchise and corporate management in life science organizations. We can help refine strategic decision making throughout the product life cycle providing enhanced visibility at complex strategic junctions: optimizing positioning in an increasingly crowded competitive landscapes, interpreting and leveraging demanding market access requirements and evaluating new revenue streams for maturing brands from new markets or indications as part of your Life Cycle Management strategy.The strategies we develop are highly individualized to each specific client and the internal needs of their organization. Everything we create is focused on how to help our clients win in a competitive environment.Our focus is to build a long term relationship with the client by working with them throughout the implementation of the strategy and ongoing competitive monitoring.

INVESTMENT BANKING and STRATEGIC ADVISORY - HEALTHCARE AND LIFE SCIENCES PHARMA - BIOTECH - DIGITAL HEALTH - HEALTH TECH - MEDICAL DEVICE I apply a unique mix of deep industry connections developed over almost 50 years of industry experience combined with an analysis of strategic alternatives to support your strategy.My network is global and spans traditional venture capital through strategic capital and partnerships as well as other sources of capital.The approach I take is highly personalized, becoming an integral part of your management team constantly evaluating feedback from investors and your team, and modifying our strategy as market conditions dictate.Four key attributes run through the process: Focus, Knowledge, Relationships, and Personal Connections.I hold FINRA registrations 63. 7, 79, 82, and SIESecurities offered through Finalis Securities LLC Member FINRA / SIPC.IPL Capital Advisory and Finalis Securities LLC are separate, unaffiliated entitiesFor more on Finalis, see below

IPL Capital Advisory is pleased to be part of the Finalis NetworkFinalis’ commitment to redefining the capital markets through innovation has made it the fastest-growing dealmaking platform with over 400 active independent investment bankers managing over 1000 active deals, many in the Life SciencesThe Finalis Platform provides IPL Capital Advisory with the opportunity to selectively partner with other like-minded bankers who can add value to specific capital-raising mandates. This enables me to combine my network developed over 50 years in the industry with other bankers with a complimentary set of relationships.Securities offered through Finalis Securities LLC Member FINRA / SIPC.IPL Capital Advisory and Finalis Securities LLC are separate, unaffiliated entities

TCA is the largest angel investment organization in the United States, with nearly 300 members in five regional Networks covering all of Southern California. Our members have invested over $115 million of their own capital in approximately 180 companies since TCA’s inception in 1997. Our portfolio companies have attracted over $1 billion in additional investment, and several of them have recently achieved successful liquidity events though acquisition or the IPO market.TCA is not just about tech; our members represent expertise in the life sciences, consumer products, financial services and many other areas that have the ability to demonstrate high growth potential. Many of our members have been or currently are entrepreneurs themselves.

BIOCOM is the largest regional life science association in the world, representing more than 550 member companies in Southern California. The association focuses on initiatives that positively influence the region’s life science community in the development and delivery of innovative products that improve health and quality of life. This includes initiatives in capital formation, public policy, workforce development, group purchasing and member services such as networking events

INVESTMENT BANKING, HEALTHCARE AND LIFE SCIENCESAs a Managing Director at Weild & Co, I apply a unique mix of deep industry connections developed over almost 50 years of industry experience combined with an analysis of strategic alternatives to support capital formation. The approach I take is highly personalized, becoming an integral part of your management team constantly evaluating feedback from investors amd modifying our strategy as market conditions dictate.Areas of focus include pharmaceutical / biotech, medical device, digital health, diagnostics and SaaS platforms related to these industries.My work spans purely strategic advisory, through capital formation and M&AMy network is global and spans traditional venture capital through strategic capital and partnerships as well as other sources of capital.I hold FINRA registrations 63. 7, and 79.Securities transactions effected through Weild & Co., member FINRA/SIPC

Objective Capital Partners, LLC is an M&A, Investment Banking firm focused on transactions for companies with enterprise values up to $500 million. Headquartered in Southern California, our seasoned professionals have collectively executed over 500 engagements in more than 35 industries. We are passionate about supporting entrepreneurs and business owners who want to maximize the value of their business and holdings.

Global Health Care Business Development.Strong focus on identifying partnerships and M&A and implementing transactions.Represent buyers looking for products as well as sellers looking for partners.Geographical expansion Japan, Europe & USSpecial expertise in Japan

Brinson Patrick Securities Corporation is an investment banking boutique serving the equity capital raising needs of publicly traded companies, from small cap to Fortune 500 for over a decade.Leveraging our DOCS® (Dynamic Offering of Common Stock) financing facility, we have worked with companies of various sizes and stages of growth to raise capital when and how they need it. We are a broker-dealer, registered with FINRA and the SEC. The DOCS® financing facility low-profile equity offering is appropriate for publicly traded companies across multiple industries. It has been successfully utilized by companies in the energy, life science, technology, real estate, financial services and hospitality industries. Through our DOCS® financing facility, Brinson Patrick enables issuers to efficiently raise capital over time as they need it, with little or no negative market impact, whether larger or smaller amounts of capital need to be raised.

The WLSA is dedicated to creating value and improving health, globally, through the convergence of communications technologies, consumers, caregivers and all sectors of the life sciences and technology environment. My role is focused on integrating companies in the pharmaceutical industry into this overall vision by working with them to understand the needs of both them and their customers and integrate their vision into this connected health continuum to better manage health and disease.

Amplyx Pharmaceuticals Inc. is a preclinical stage company that re-engineers small molecule drugs and improves their safety and efficacy with two approaches.

LiquidGrds empowers life science companies to listen, understand and strategically engage in the online health dialogue.

InterPharmaLink is a leading provider of professional strategic, corporate development, and business development services to life science companies.

Cabrillo Advisors is a Southern California based investment banking firm staffed with experienced professionals trained at top-tier institutions.Our mission is to provide high-quality mergers, acquisitions, capital raising expertise and strategic advisory services to middlemarket companies that are traditionally underserved by larger firms. Further, we bring an extensive network of Investors, lenders, and Strategic Buyers to bear on behalf of our clients.

Jack was Corporate Development for Vital Therapies. This includes developing and implementing a commercialization strategy for China where their key product, ELAD®, will initially launch in 2007 as well as for the US where a launch is planned for 2008. In his role, he is also responsible for Corporate Communications and Public Relations, partnering, and assists in Capital Development and general business and therapeutic strategy development.

Over this period I joined three different pharmaceutical or medical device companies. Although each of these roles were part time, in each case I was an active member of the executive management team. The companies were;Biota, IncInfaCareOpticon

15 different roles over a 30 year career, including:Team Leader, Global Late Life Cycle Products TeamDirector, Marketing Support – Pharmaceutical ProductsMarketing Director- Global Neuroscience Business UnitMarketing Director – U S Marketing for Anti Infectives, GI, and Neuroscience including the launch of ZYPREXAExecutive Director – European Marketing - LondonDirector – U S Marketing Research Director – Global Pharmaceutical Pricing Development Manager – U S Product Management and U S Market ResearchSales Manager – U S AffiliateMarketing Planing, Marketing Research and Pricing AssociateSales Representative – U S Affiliate